NASDAQ$MURA
Mural Oncology Plc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Mural Oncology announced second quarter 2024 financial results and provided an update on pipeline progress.
Mural Oncology reported a net loss of $31.6 million for the second quarter of 2024, with cash, cash equivalents, and marketable securities totaling $204.7 million as of June 30, 2024. The company reaffirms its cash runway guidance into the fourth quarter of 2025 and anticipates readouts from nemvaleukin alfa in two late-stage clinical trials in the first half of 2025.
- Mural appointed George Golumbeski, Ph.D., to its board of directors in July.
- Late-stage clinical trials of nemvaleukin alfa continue to progress toward readouts in the first half of 2025, focusing on two foundational indications.
- Candidate nominations for Mural’s IL-18 and IL-12 programs are expected later this year.
- Company reaffirms guidance that its cash, cash equivalents, and marketable securities are expected to fund its operations into the fourth quarter of 2025.
Headline financials
Revenue & EPS history
Mural Oncology · Revenue · Quarterly
$0
Forward guidance
The company reaffirms guidance that its cash, cash equivalents, and marketable securities are expected to fund its operations into the fourth quarter of 2025. Management forecasts lower operating expenses in 2025 versus 2024 due to the timing of clinical trial expenses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q2 2024
-9.3%
Avg return
Earnings day
-9.4%
Avg return
5 days after
+5.1%
Avg return
30 days after
23%
3 / 13 earnings
Positive
+14.6%
Q4 2023
Best reaction
-61.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -0.5% | -0.5% | — | |
| Q2 2025 | -20.2% | -30.3% | -9.2% | |
| Q1 2025 | -4.4% | -4.7% | -10.9% | |
| Q4 2024 | -61.6% | -65.0% | -31.3% | |
| Q3 2024 | -0.9% | -4.8% | +2.3% | |
| Q2 2024 | +1.0% | +4.5% | +0.6% | |
| Q1 2024 | +2.7% | +4.0% | -12.0% | |
| Q4 2023 | +14.6% | +13.2% | -16.7% | |
| Q1 2023 | -10.4% | -7.7% | +27.7% | |
| Q2 2023 | -10.4% | -7.7% | +27.7% | |
| Q3 2022 | -10.4% | -7.7% | +27.7% | |
| Q4 2022 | -10.4% | -7.7% | +27.7% | |
| Q3 2023 | -10.4% | -7.7% | +27.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro